Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025
Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.
Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care
Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.
Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer
Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors
Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.
Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL
Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.
